Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2009

01-05-2009 | Original Article

[18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1

Authors: Victoria S. Warbey, Rosalie E. Ferner, Joel T. Dunn, Eduardo Calonje, Michael J. O’Doherty

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2009

Login to get access

Abstract

Purpose

The detection of malignant peripheral nerve sheath tumours (MPNSTs) in patients with neurofibromatosis 1 (NF1) remains a clinical challenge. The purpose of this study was to evaluate the use of [18F]2-fluoro-2-deoxy-d-glucose PET/CT (FDG PET/CT with early and delayed imaging) in patients with symptomatic neurofibromas, to revalidate current cut-off values for identification of malignant change within neurofibromas and to examine the relationship between SUV and tumour grade.

Methods

Patients with symptomatic neurofibromas underwent FDG PET/CT imaging at 90 and 240 min. Semiquantitative analysis using maximum standardized uptake value (SUVmax) was performed and correlated with histology.

Result

In 69 patients, 85 lesions were identified for analysis, including 10 atypical neurofibromas and 21 MPNSTs. Sensitivity of FDG PET/CT in diagnosing NF1-associated MPNST was 0.97 (95% CI 0.81–0.99) and the specificity was 0.87 (CI 0.74–0.95). There was a significant difference in SUVmax between early and delayed imaging and in SUVmax between tumours identified as benign and malignant on PET/CT. There was also a significant difference in SUVmax between tumour grades.

Conclusion

FDG PET/CT is a highly sensitive and specific imaging modality for the diagnosis of MPNST in NF1 patients. We recommend performing early (90 min) and delayed imaging at 4 h for accurate lesion characterization and using a cut-off SUVmax of 3.5 on delayed imaging to achieve maximal sensitivity.
Literature
1.
go back to reference Compston DAS, Clark P, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 1989;26(11):704–11.PubMedCrossRef Compston DAS, Clark P, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 1989;26(11):704–11.PubMedCrossRef
2.
go back to reference Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol 2007;6(4):340–51.PubMedCrossRef Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol 2007;6(4):340–51.PubMedCrossRef
3.
go back to reference Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumours in neurofibromatosis 1. Cancer Res 2002;62:1573–7.PubMed Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumours in neurofibromatosis 1. Cancer Res 2002;62:1573–7.PubMed
4.
go back to reference Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002;39(5):311–4.PubMedCrossRef Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002;39(5):311–4.PubMedCrossRef
5.
go back to reference Ferner RE, Lucas JD, O’Doherty MJ, Hughes RAC, Smith MA, Cronin BF, et al. Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDGPET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatr 2000;68:353–7.PubMedCrossRef Ferner RE, Lucas JD, O’Doherty MJ, Hughes RAC, Smith MA, Cronin BF, et al. Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDGPET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatr 2000;68:353–7.PubMedCrossRef
6.
go back to reference Cardona S, Schwarzbach M, Hinz U, Dimitrakopoulou-Strauss A, Attigah N, Mechtersheimer G, et al. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol 2003;29:536–41.PubMedCrossRef Cardona S, Schwarzbach M, Hinz U, Dimitrakopoulou-Strauss A, Attigah N, Mechtersheimer G, et al. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol 2003;29:536–41.PubMedCrossRef
7.
go back to reference Brenner W, Friedrich RE, Gawad KA, Hagel C, von Deimling A, de Witt M, et al. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging 2006;33:428–32.PubMedCrossRef Brenner W, Friedrich RE, Gawad KA, Hagel C, von Deimling A, de Witt M, et al. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging 2006;33:428–32.PubMedCrossRef
8.
go back to reference Bredella MA, Torriani M, Hornicek F, Ouellette HA, Palmer WE, Williams Z, et al. Value of PET in the assessment of patients with neurofibromatosis type 1. AJR Am J Roentgenol 2007;189:928–35.PubMedCrossRef Bredella MA, Torriani M, Hornicek F, Ouellette HA, Palmer WE, Williams Z, et al. Value of PET in the assessment of patients with neurofibromatosis type 1. AJR Am J Roentgenol 2007;189:928–35.PubMedCrossRef
9.
go back to reference Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 2008;19(2):390–4.PubMedCrossRef Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 2008;19(2):390–4.PubMedCrossRef
10.
go back to reference Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histological grading system. Int J Cancer 1984;33(1):37–42.PubMedCrossRef Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histological grading system. Int J Cancer 1984;33(1):37–42.PubMedCrossRef
11.
go back to reference Valeyrie-Allanore L, Ortonne N, Lantieri L, Ferkal S, Wechsler J, Bagot M, et al. Histopathologically dysplastic neurofibromas in neurofibromatosis 1: diagnostic criteria, prevalence and clinical significance. Br J Dermatol 2008;58:1008–12.CrossRef Valeyrie-Allanore L, Ortonne N, Lantieri L, Ferkal S, Wechsler J, Bagot M, et al. Histopathologically dysplastic neurofibromas in neurofibromatosis 1: diagnostic criteria, prevalence and clinical significance. Br J Dermatol 2008;58:1008–12.CrossRef
12.
go back to reference Lin BT-Y, Weiss LM, Medeiros LJ, Jeffrey L. Neurofibroma and cellular neurofibroma with atypia: a report of 14 tumors. Am J Surg Pathol 1997;21:1443–9.PubMedCrossRef Lin BT-Y, Weiss LM, Medeiros LJ, Jeffrey L. Neurofibroma and cellular neurofibroma with atypia: a report of 14 tumors. Am J Surg Pathol 1997;21:1443–9.PubMedCrossRef
13.
go back to reference Lodge MA, Lucas JD, Marsden PK, Cronin BF, O’Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med Mol Imaging 1999;26:22–30.CrossRef Lodge MA, Lucas JD, Marsden PK, Cronin BF, O’Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med Mol Imaging 1999;26:22–30.CrossRef
14.
go back to reference Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumours. A clinicopathologic study of 120 cases. Cancer 1986;58:2006–21.CrossRef Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumours. A clinicopathologic study of 120 cases. Cancer 1986;58:2006–21.CrossRef
15.
go back to reference Visvikis D, Costa DC, Croasdale I, Lonn AHR, Bomanji J, Gacinovic S, et al. CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET. Eur J Nucl Med Mol Imaging 2003;30:344–53.PubMed Visvikis D, Costa DC, Croasdale I, Lonn AHR, Bomanji J, Gacinovic S, et al. CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET. Eur J Nucl Med Mol Imaging 2003;30:344–53.PubMed
16.
go back to reference Somer EJ, Benatar NA, O’Doherty MJ, Smith MA, Marsden PK. Use of the CT component of PET-CT to improve PET-MR registration: demonstration in soft tissue sarcoma. Phys Med Biol 2007;52:6991–7006.PubMedCrossRef Somer EJ, Benatar NA, O’Doherty MJ, Smith MA, Marsden PK. Use of the CT component of PET-CT to improve PET-MR registration: demonstration in soft tissue sarcoma. Phys Med Biol 2007;52:6991–7006.PubMedCrossRef
Metadata
Title
[18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1
Authors
Victoria S. Warbey
Rosalie E. Ferner
Joel T. Dunn
Eduardo Calonje
Michael J. O’Doherty
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-1038-0

Other articles of this Issue 5/2009

European Journal of Nuclear Medicine and Molecular Imaging 5/2009 Go to the issue